Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Epilepsy 2Small Cell Lung Carcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × LY3295668 erbumine × Clear all
NCT03898791 2021-08-05

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Eli Lilly and Company

Phase 1 Completed
48 enrolled
Thoracic

Epilepsy, Small Cell Lung Carcinoma

NCT03955939 2020-06-01

A Study of LY3295668 Erbumine in Participants With Breast Cancer That Has Spread to Other Parts of the Body

Eli Lilly and Company

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Epilepsy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡